Cognition Therapeutics, Inc. (CGTX)

NASDAQ: CGTX · IEX Real-Time Price · USD
6.25 -0.22 (-3.40%)
Jan 14, 2022 4:00 PM EST - Market closed
Market Cap137.73M
Revenue (ttm)n/a
Net Income (ttm)-5.11M
Shares Out22.04M
EPS (ttm)-0.23
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume44,131
Open6.30
Previous Close6.47
Day's Range6.21 - 6.45
52-Week Range4.68 - 13.80
Betan/a
AnalystsStrong Buy
Price Target24.50 (+292.0%)
Earnings Daten/a

About CGTX

Cognition Therapeutics is a clinical-stage biopharmaceutical company engaged in the discovery and development of innovative, small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Since our inception, we have collaborated and worked closely with key healthcare organizations and thought leading institutions in the field of degenerative diseases to develop and advance our therapeutic candidates. To date we have been awarded approximately $168.4 million in grants and financia...

IndustryBiotechnology
IPO DateOct 8, 2021
CEOLisa Ricciardi
Employees15
Stock ExchangeNASDAQ
Ticker SymbolCGTX
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 2 analysts, the average rating for CGTX stock is "Strong Buy." The 12-month stock price forecast is 24.50, which is an increase of 292.00% from the latest price.

Price Target
$24.50
(292.00% upside)
Analyst Consensus: Strong Buy

News

Cognition Therapeutics Provides Update on Corporate and Pipeline Progress and Reviews Goals for 2022

PURCHASE, N.Y., Jan. 10, 2022 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical-stage biopharmaceutical company engaged in the discovery and development of innovative, small mo...

5 days ago - GlobeNewsWire

Cognition Therapeutics to Participate in Next-Generation Alzheimer's Disease Panel at Virtual Biotech Showcase on Jan...

Lisa Ricciardi, CEO, to participate as a Panelist in, “Aduhelm: Stimulating the Next- Generation of AD Treatment” Lisa Ricciardi, CEO, to participate as a Panelist in, “Aduhelm: Stimulating the Next- Ge...

3 weeks ago - GlobeNewsWire

Cognition Therapeutics to Host Virtual R&D Symposium December 7 on Dementia with Lewy Bodies and the Potential for Si...

PURCHASE, N.Y., Nov. 30, 2021 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical-stage biopharmaceutical company engaged in the discovery and development of innovative, small mo...

1 month ago - GlobeNewsWire

Cognition Therapeutics Reports Third Quarter Financial Results and Company Highlights

Capital from upsized IPO plus substantial NIA grants supports clinical progress of novel small-molecule σ-2 modulators into new indications Capital from upsized IPO plus substantial NIA grants supports ...

1 month ago - GlobeNewsWire

3 Companies That Went Public Last Month

Are these IPOs right for you?

Other symbols:GTLBPTLO
2 months ago - The Motley Fool

Pittsburgh Life Sciences Greenhouse Proudly Announces IPO of Portfolio Company Cognition Therapeutics

PITTSBURGH, Oct. 12, 2021 /PRNewswire/ --  Pittsburgh Life Science Greenhouse (PLSG) is proud to share that one of its portfolio companies, Cognition Therapeutics, Inc., launched an initial public offer...

3 months ago - PRNewsWire

Cognition Therapeutics raised more than $45 million after IPO priced in the middle of the expected range

Cognition Therapeutics Inc.'s stock CGTX, is set to start trading Friday, after the New York-based biopharmaceutical company targeting treatments for central nervous systems disorders said its upsized i...

3 months ago - Market Watch

Cognition Therapeutics Announces Pricing of Upsized Initial Public Offering

PURCHASE, N.Y., Oct. 08, 2021 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company engaged in the discovery and development of innovative, small molecule therapeu...

3 months ago - GlobeNewsWire

Cognition Therapeutics Announces Launch of its Initial Public Offering

PURCHASE, N.Y., Oct. 04, 2021 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company engaged in the discovery and development of innovative, small molecule therapeu...

3 months ago - GlobeNewsWire